Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
2/28/2025 | 2/28/2024 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Revenue | $156 | $142 | $128 | $120 |
| % Growth | 10.1% | 10.4% | 6.8% | – |
| Cost of Goods Sold | $65 | $63 | $56 | $50 |
| Gross Profit | $91 | $79 | $73 | $70 |
| % Margin | 58.5% | 55.7% | 56.7% | 58.3% |
| R&D Expenses | $0 | $9 | $10 | $11 |
| G&A Expenses | $27 | $25 | $23 | $21 |
| SG&A Expenses | $72 | $57 | $51 | $50 |
| Sales & Mktg Exp. | $35 | $32 | $28 | $30 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $72 | $66 | $61 | $61 |
| Operating Income | $19 | $13 | $12 | $9 |
| % Margin | 12.1% | 9.3% | 9% | 7.8% |
| Other Income/Exp. Net | $10 | $6 | $5 | $4 |
| Pre-Tax Income | $29 | $19 | $16 | $13 |
| Tax Expense | $6 | $5 | $4 | $3 |
| Net Income | $22 | $14 | $12 | $10 |
| % Margin | 13.9% | 9.9% | 9.1% | 8% |
| EPS | 295.57 | 181.61 | 148 | 118.92 |
| % Growth | 62.7% | 22.7% | 24.5% | – |
| EPS Diluted | 295.15 | 181.42 | 147.87 | 118.84 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $5 | $5 | $4 |
| EBITDA | $35 | $24 | $17 | $17 |
| % Margin | 22.5% | 17.2% | 12.9% | 14.4% |